Clinical Trial Update: SRS Sequential Sindilimab in Brain Metastasis of NSLSC [Phase 2]

View source ↗

Summary

Phase 2 trial update for sequential sintilimab (SRS) in brain metastases from NSCLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Xiaorong Dong | Conditions: NSCLC Stage IV, Brain Metastases | Phase 2 | Status: UNKNOWN